Citations

Mayo Clinic

Showing 10 of 108551 citations.

Clinical course of patients with incidental finding of 20q‐ in the bone marrow without a morphologic evidence of myeloid neoplasm
Jawad, Majd, Oliveira, Jennifer L. , Hoyer, James D., Hook, C. Christopher , Herrick, Jennifer L. , Jawad, Majd D, Shi, Min , Go, Ronald S.

American Journal of Hematology | March 1, 2016 | Volume: 91 | Issue: 6 | Pages: 556-559

10.1002/ajh.24347 | PMID 26928533 Get It

Deletion of the long arm of chromosome 20 (20q‐) is a frequent finding in bone marrow karyotypes, mainly associated with myeloid neoplasms (MNs). Its clinical significance in the setting of normal bone marrow morphology is unclear. We described the clinical characteristics, cytogenetic findings, and outcome of 102 such patients seen at our institution from 2000‐2014. Their median age was 66 years. The indication for bone marrow biopsy was either unexplained cytopenias (48%) or hematologic cancer staging/reevaluation (52%). In 88 (86%) patients, 20q‐ was an isolated finding. Thirty‐nine (38%) patients previously received chemotherapy and 88 (86%) had cytopenias at the time of 20q‐ finding. After a median of 35 months, 12 (13%) patients developed MNs: 10 myelodysplastic syndromes, one acute myeloid leukemia and one myeloproliferative neoplasm. None of 14 patients with normal blood counts, but 7 of 35 (20%) with mild cytopenias, and 5 of 53 (9%) with moderate/severe cytopenias developed MNs. We did not find an association between the number of metaphases with 20q‐ and the development of MN. The incidental finding of 20q‐ in the bone marrow generally does not portend an early stage MN. Particularly, those without cytopenias at the time of diagnosis may have a good prognosis. Am. J. Hematol. 91:556–559, 2016. © 2016 Wiley Periodicals, Inc.
Evidence on Use of Neuroimaging for Surgical Treatment of Temporal Lobe Epilepsy
Jones, Amy L., Cascino, Gregory D.

JAMA Neurology | March 1, 2016 | Volume: 73 | Issue: 4 | Pages: 464

10.1001/jamaneurol.2015.4996 | PMID 26926529 Get It

Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment
Schak, Kathryn M. , Voort, Jennifer L. Vande , Johnson, Emily K. , Kung, Simon , Leung, Jonathan G. , Rasmussen, Keith G., Palmer, Brian A. , Frye, Mark A. , Vande Voort, Jennifer L., Leung, Jonathan G

American Journal of Psychiatry | March 1, 2016 | Volume: 173 | Issue: 3 | Pages: 215-218

10.1176/appi.ajp.2015.15081082 | PMID 26926127 Get It

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Petrylak, Daniel P. , Tagawa, Scott T. , Eisen, Andrea , Canil, Christina , Burke, John M. , Shaffer, David R. , Pan, Chong‐Xian, Aragon‐Ching, Jeanny B. , Tang, Shande, Zhang, Hui , Cavanaugh, Christopher , Gao, Ling , Walgren, Richard A., Kohli, Manish , Spira, Alexander, Yu, Evan Y., Shaffer, David, Kim, Jenny J, Aragon-Ching, Jeanny B, Quinn, David I, Vogelzang, Nicholas J. , Cavanaugh, Christopher T, Kauh, John S, Chi, Kim N, Sridhar, Srikala S , Spira, Alexander I. , Yu, Evan Y , Kim, Jaeyeon , Quinn, David I , Kauh, John Sae Wook , N., Kim , Tagawa, Scott T , Eisen, Andrea

Journal of Clinical Oncology | March 1, 2016 | Volume: 34 | Issue: 13 | Pages: 1500-1509

10.1200/jco.2015.65.0218 | PMID 26926681 Get It

Purpose This trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody) or icrucumab (vascular endothelial growth factor receptor 1 antibody) after progression during or within 12 months of platinum-based regimens for patients with locally advanced or metastatic urothelial carcinoma. Patients and Methods Patients were randomly assigned (1:1:1) to receive docetaxel 75 mg/m2 intravenously (IV) on day 1 of a 3-week cycle (arm A), docetaxel 75 mg/m2 IV plus ramucirumab 10 mg/kg IV on day 1 of a 3-week cycle (arm B), or docetaxel 75 mg/m2 IV on day 1 plus icrucumab 12 mg/kg IV on days 1 and 8 of a 3-week cycle (arm C). Treatment continued until disease progression or unacceptable toxicity. The primary end point was investigator-assessed progression-free survival (PFS). Results A total of 140 patients were randomly assigned and treated in arms A (n = 45), B (n = 46), or C (n = 49). PFS was significantly longer in arm B compared with arm A (median, 5.4 months; 95% CI, 3.1 to 6.9 months v 2.8 months; 95% CI, 1.9 to 3.6 months; stratified hazard ratio, 0.389; 95% CI, 0.235 to 0.643; P = .0002). Arm C did not experience improved PFS compared with arm A (1.6 months; 95% CI, 1.4 to 2.9; stratified hazard ratio, 0.863; 95% CI, 0.550 to 1.357; P = .5053). The most common grade 3 or worse adverse events (arms A, B, and C) were neutropenia (36%, 33%, and 39%), fatigue (13%, 30%, and 20%), febrile neutropenia (13%, 17%, and 6.1%), and anemia (6.7%, 13%, and 14%, respectively). Conclusion The addition of ramucirumab to docetaxel met the prespecified efficacy end point for prolonging PFS in patients with locally advanced or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation in the phase III setting.
Stabilization of Volar Ulnar Rim Fractures of the Distal Radius: Current Techniques and Review of the Literature
O’Shaughnessy, Maureen , O'Shaughnessy, Maureen A, Shin, Alexander Y. , Kakar, Sanjeev

Journal of Wrist Surgery | March 1, 2016 | Volume: 05 | Issue: 02 | Pages: 113-119

10.1055/s-0036-1579549 | PMID 27104076 Get It

Incidence of and Factors Associated With the Decision to Undergo Anterior Cruciate Ligament Reconstruction 1 to 10 Years After Injury
Sanders, Thomas L. , Kremers, Hilal Maradit , Bryan, Andrew J., Kremers, Walter K. , Levy, Bruce A. , Dahm, Diane L., Krych, Aaron J. , Maradit Kremers, Hilal, Stuart, Michael J. , Krych, Aaron J , Maradit Kremers, Hilal , Kremers, Walter K

The American Journal of Sports Medicine | February 29, 2016 | Volume: 44 | Issue: 6 | Pages: 1558-1564

10.1177/0363546516630751 | PMID 26928338 Get It

Background: Among patients treated nonoperatively for 1 year after anterior cruciate ligament (ACL) disruption, little is known about the frequency of ACL reconstruction within the first year of injury and the effect of age range, sex, and meniscal tears on the incidence of ACL reconstruction between 1 and 10 years after injury. Purpose: To (1) define the rate of delayed ACL reconstruction (between 1 and 10 years after injury) in a population-based cohort of isolated ACL tears and (2) evaluate predictive factors associated with delayed reconstruction. Study Design: Case-control study; Level of evidence, 3. Methods: The study included a population-based cohort of 1841 patients with new-onset, isolated ACL tears that occurred between January 1, 1990, and December 31, 2010. The complete medical records were reviewed to confirm diagnosis and collect data on clinical characteristics and details of subsequent ACL surgery. To evaluate the incidence of ACL reconstruction between 1 and 10 years after injury, landmark survival analysis was performed with a landmark set at 1 year after injury. Early and late predictors of ACL reconstruction were analyzed using Cox proportional hazards regression. Results: A total of 661 patients were treated nonoperatively for the first year after ACL tears. Over a mean 10 years of follow-up, 213 patients (32%) underwent ACL reconstruction between 1 and 10 years after injury. Young age (hazard ratio [HR], 0.55 per decade increase in age; 95% CI, 0.48-0.62) and meniscal tear at injury (HR, 1.48; 95% CI, 1.12-1.95) were significant predictors of undergoing delayed reconstruction. The rate of delayed ACL reconstruction decreased significantly over the study period ( P < .03). There was no association between sex (HR, 0.89; 95% CI, 0.67-1.16) and delayed ACL reconstruction. Among patients who had delayed ACL reconstruction, 40% experienced a secondary meniscal tear before surgery. Conclusion: In this study population of 1841 patients, 62% of patients received ACL reconstruction within 1 year of injury. Of patients treated nonoperatively for 1 year after ACL tears, 32% underwent delayed ACL reconstruction. Predictors of reconstruction beyond 1 year were young age (50% reduction in reconstruction per decade increased age) and baseline meniscal tear. Sex was not predictive for reconstruction beyond 1 year from injury.
Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm
Sun, Xiangqing , Elston, Robert C. , Barnholtz‐Sloan, Jill S. , Faulx, Ashley L., Mittal, Sumeet K. , Shaheen, Nicholas J. , Wang, Jean S. , Iyer, Prasad G. , Tian, Ye D. , Willis, Joseph , Guda, Kishore , Markowitz, Sanford D. , Chandar, Apoorva K., Warfe, James M. , Brock, Wendy , Chak, Amitabh , Falk, Gary W. , Grady, William M. , Canto, Marcia Irene , Abrams, Julian A , Willis, Joseph E , Barnholtz-Sloan, Jill S

Cancer Epidemiology, Biomarkers & Prevention | February 29, 2016 | Volume: 25 | Issue: 5 | Pages: 727-735

10.1158/1055-9965.epi-15-0832 | PMID 26929243 Get It

Abstract Background: Barrett's esophagus is often asymptomatic and only a small portion of Barrett's esophagus patients are currently diagnosed and under surveillance. Therefore, it is important to develop risk prediction models to identify high-risk individuals with Barrett's esophagus. Familial aggregation of Barrett's esophagus and esophageal adenocarcinoma, and the increased risk of esophageal adenocarcinoma for individuals with a family history, raise the necessity of including genetic factors in the prediction model. Methods to determine risk prediction models using both risk covariates and ascertained family data are not well developed. Methods: We developed a Barrett's Esophagus Translational Research Network (BETRNet) risk prediction model from 787 singly ascertained Barrett's esophagus pedigrees and 92 multiplex Barrett's esophagus pedigrees, fitting a multivariate logistic model that incorporates family history and clinical risk factors. The eight risk factors, age, sex, education level, parental status, smoking, heartburn frequency, regurgitation frequency, and use of acid suppressant, were included in the model. The prediction accuracy was evaluated on the training dataset and an independent validation dataset of 643 multiplex Barrett's esophagus pedigrees. Results: Our results indicate family information helps to predict Barrett's esophagus risk, and predicting in families improves both prediction calibration and discrimination accuracy. Conclusions: Our model can predict Barrett's esophagus risk for anyone with family members known to have, or not have, had Barrett's esophagus. It can predict risk for unrelated individuals without knowing any relatives' information. Impact: Our prediction model will shed light on effectively identifying high-risk individuals for Barrett's esophagus screening and surveillance, consequently allowing intervention at an early stage, and reducing mortality from esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 25(5); 727–35. ©2016 AACR.
Paving the TRAIL to anti‐fibrotic therapy
Guicciardi, Maria Eugenia , Gores, Gregory J.

Hepatology | February 29, 2016 | Volume: 64 | Issue: 1 | Pages: 29-31

10.1002/hep.28520 | PMID 26925875 Get It

Update on Pulmonary Fibrosis: Not All Fibrosis Is Created Equally
Smith, Maxwell L.

Archives of Pathology & Laboratory Medicine | February 29, 2016 | Volume: 140 | Issue: 3 | Pages: 221-229

10.5858/arpa.2015-0288-sa | PMID 26927716 Get It

Context Three distinct patterns of pulmonary fibrosis, including usual interstitial pneumonia, fibrotic nonspecific interstitial pneumonia, and airway-centered fibrosis, can be identified on surgical lung biopsies. Objectives To compare the pathologic definitions, clinical and radiographic presentations, etiologies and differential diagnoses, treatments, and prognoses of usual interstitial pneumonia, fibrotic nonspecific interstitial pneumonia, and airway-centered fibrosis patterns, and to address the challenges and controversies related to pulmonary fibrosis. Data Sources Data were derived from published literature and clinical experience. Conclusions Although there may be overlap, identification of the dominant form of fibrosis in a particular case can provide a general category of disease and assist in identifying an etiology.
Pulmonary Langerhans Cell Histiocytosis: An Update From the Pathologists' Perspective
Roden, Anja C. , Yi, Eunhee S.

Archives of Pathology & Laboratory Medicine | February 29, 2016 | Volume: 140 | Issue: 3 | Pages: 230-240

10.5858/arpa.2015-0246-ra | PMID 26927717 Get It

Context Pulmonary Langerhans cell histiocytosis (PLCH) is a rare histiocytic disorder that almost exclusively affects the lungs of smokers. PLCH is characterized by bronchiolocentric nodules and/or cysts in an upper and mid lung distribution with sparing of the costophrenic angles. The diagnosis can be challenging and often requires transbronchial biopsy or surgical lung biopsy. Pulmonary hypertension is a relatively common and sometimes severe complication of PLCH. The pathogenesis of PLCH is still debated. Recently, BRAF V600E mutation and BRAF expression have been identified in some patients with PLCH, suggesting that at least a subset of PLCH has a clonal proliferation. While smoking cessation is the first-line treatment of PLCH, some patients might require additional treatment and eventually transplant. Given that the lesional cells of PLCH express BRAF in some patients, MAPKinase pathway–targeted treatment might be useful for therapy-resistant patients. Objective —To present the more recently recognized clinical and pathologic aspects of PLCH, including pulmonary hypertension in PLCH, pathogenesis, and treatment, as well as the basic diagnostic approach to PLCH. Data Sources Authors' own research, and search of literature database (PubMed) and UpToDate. Conclusions —Despite the recent progress, more studies are needed to elucidate the biology of PLCH for identification of prognostic factors and appropriate treatment options, especially for therapy-refractory PLCH cases.